NATALIE VANDERBLEEK: Open Payments
NPI 1861033508 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$956 in 41 payments from 15 companies in 2025. Trend: 2023 $78 · 2024 $197 · 2025 $956
Food & beverage: $956
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 10 | $185 |
| Amgen Inc. | 8 | $134 |
| Novo Nordisk Inc | 1 | $117 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 1 | $108 |
| Novartis Pharmaceuticals Corporation | 4 | $71 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $57 |
| Alnylam Pharmaceuticals Inc. | 3 | $55 |
| AstraZeneca Pharmaceuticals LP | 3 | $49 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $35 |
Products named: VYNDAQEL, REPATHA, Ozempic, LifeVest, Kerendia, LEQVIO, AMVUTTRA, FARXIGA.
Industry payments across AL — which companies pay providers there.
